Skandinaviska Enskilda Banken (SEB)’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-113,700
Closed -$1.98M 1130
2020
Q4
$1.98M Buy
113,700
+21,400
+23% +$381K 0.01% 654
2020
Q3
$1.69M Buy
92,300
+46,500
+102% +$865K 0.01% 617
2020
Q2
$818K Buy
+45,800
New +$775K 0.01% 755

Other funds holding CHRS

Skandinaviska Enskilda Banken (SEB)'s CHRS Position: Q1 2021 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Coherus Oncology (CHRS) in Q1 2021, closing a stake of 113,700 shares — an estimated $1.98M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in CHRS in Q2 2020 and held it in 3 quarters. The position peaked at $1.98M in Q4 2020. 205 funds tracked by Wall St. Rank hold CHRS as of Q1 2021.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Coherus Oncology position as of Q1 2021 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 113,700 Coherus Oncology shares in Q1 2021, an estimated $1.98M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Coherus Oncology in Q2 2020 and held it in 3 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Coherus Oncology position peaked at $1.98M in Q4 2020.
  • 205 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2021.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2021, filed 14 May 2021.